Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Maximilian Stahl, Jan Philipp Bewersdorf, Rahul Vedula, Yiwen Liu, H. Moses Murdock, Harrison Tsai, Evan Chen, Benjamin Rolles, Nikolai Podoltsev, Lourdes Mendez, Luca Lanino, Alain Mina, Luis E. Aguirre, Mikkael Sekeres, Lionel Ades, R. Coleman Lindsley, Amer Zeidan

Blood (2025) 146 (Supplement 1): 5651.

https://doi.org/10.1182/blood-2025-5651

Published: 2025

Journal Articles

Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

Konan Beke, Abdulrahman Alhajahjeh, Alyssa Grimshaw, Nikolai Podoltsev, Lourdes Mendez, Maximilian Stahl, Amer Zeidan, Jan Philipp Bewersdorf

Blood (2025) 146 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2025-5154

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 3859.

https://doi.org/10.1182/blood-2025-3859

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2025-2068

Published: 2025

Journal Articles

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Guillermo Garcia-Manero, Manuel Ugidos, Maroof Hasan, Matthew Stokes, Matteo Della Porta, Amer Zeidan, Valeria Santini, Uwe Platzbecker, Rami Komrokji, Dimana Miteva, Veronika Pozharskaya, Anita Gandhi, Daniel Lopes de Menezes, Rajasekhar Suragani

Blood (2025) 146 (Supplement 1): 5613.

https://doi.org/10.1182/blood-2025-5613

Published: 2025

Journal Articles

Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?

Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Olisaemeka Ogbue, Matteo D'Addona, Ahmad Kiwan, Hussein Awada, Simona Pagliuca, Hetty Carraway, Amer Zeidan, Suresh Kumar Balasubramanian, Taha Bat, Yazan Madanat, Valeria Visconte, Jaroslaw Maciejewski

Blood (2025) 146 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2025-3485

Published: 2025

Journal Articles

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Valeria Santini, Matteo Della Porta, Rami Komrokji, Veronika Pozharskaya, Thalia Farazi, Karen Keeperman, Yinzhi Lai, Dimana Miteva, Tracy Krimmel, Barkha Aggarwal, David Valcarcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Guillermo Garcia-Manero, Amer Zeidan

Blood (2025) 146 (Supplement 1): 792.

https://doi.org/10.1182/blood-2025-792

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Cameron Hunter, Karthik Chetlapalli, Satoko Ito, Jan Philipp Bewersdorf, Prajwal Boddu, Sabrina Browning, Stephanie Halene, Terri Parker, Scott Huntington, Shalin Kothari, Lourdes Mendez, Natalia Neparidze, Tarsheen Sethi, Maximilian Stahl, Nikolai Podoltsev, Amer Zeidan, Rory Shallis, George Goshua

Blood (2025) 146 (Supplement 1): 6208.

https://doi.org/10.1182/blood-2025-6208

Published: 2025

Journal Articles

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Amer Zeidan, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Mika Kontro, Naval Daver

Blood (2025) 146 (Supplement 1): 236.

https://doi.org/10.1182/blood-2025-236

Published: 2025

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Rong Wang, Jessica Stempel, Rory Shallis, Jan Philipp Bewersdorf, Lourdes Mendez, Maximilian Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2025-6393

Published: 2025

Journal Articles

Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States

Jessica Stempel, Rong Wang, Rory Shallis, Lourdes Mendez, Jan Philipp Bewersdorf, Maximilian Stahl, Amer Zeidan, Xiaomei Ma, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 6392.

https://doi.org/10.1182/blood-2025-6392

Published: 2025

Journal Articles

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Blood (2025) 146 (Supplement 1): 48.

https://doi.org/10.1182/blood-2025-48

Published: 2025

Journal Articles

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Mika Kontro, Anthony Selwyn Stein, Johanna Rimpiläinen, Marja Pyörälä, Timo Siitonen, Brian Ball, Mikko Myllymäki, Joshua Zeidner, Dr. Emma Searle, Ruth Witherall, Petri Bono, Aneel Nimba, Joab Williamson, Sofia Aakko, Maija Hollmén, Amer Zeidan, Naval Daver

Blood (2025) 146 (Supplement 1): 5627.

https://doi.org/10.1182/blood-2025-5627

Published: 2025

Journal Articles

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Blood (2025) 146 (Supplement 1): 490.

https://doi.org/10.1182/blood-2025-490

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Menin inhibitors for NPM1-mutated and KMT2A-rearranged relapsed/refractory acute myeloid leukemia (AML): A systematic review and meta-analysis

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes

Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial

Which molecular patterns of high-risk myeloid malignancies are concordantly identified using two machine learning algorithms?

Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trial

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Early discharge program cost savings for patients with newly diagnosed acute myeloid leukemia after intensive induction chemotherapy

Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Treatment initiation and first line tyrosine kinase inhibitor (TKI) selection for older patients with newly diagnosed chronic myeloid leukemia (CML) in the United States (US) before and after the introduction of generic imatinib (GE-IMA)

Impact of metformin on the incidence of thrombotic events in older patients with polycythemia vera and essential thrombocythemia in the United States

Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study

Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only